amie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Center
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 2, 2021 Category: Universities & Medical Training Tags: News Source Type: news
Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca ' s COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination.
The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is ins...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news
Antifungal drug improves key cystic fibrosis biomarkers in clinical study
(University of Illinois at Urbana-Champaign, News Bureau) A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with cystic fibrosis, a clinical study by researchers at the University of Illinois Urbana-Champaign and the University of Iowa found. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 17, 2020 Category: Biology Source Type: news
Featured Review: Drugs for correcting the basic defect in the most common cystic fibrosis-causing gene variant
Read thisrecently published Cochrane review about CFTR correctors, a therapy for cystic fibrosis targeted at specific variants (most commonly F508del)In this review, the authors looked at drugs (or drug combinations) for correcting the basic defect in the most common cystic fibrosis (CF)-causing gene variant (F508del) and assessed their impact on outcomes important to people with Cystic Fibrosis, e.g. survival, quality of life (QoL), lung function and safety.Professor Kevin Southern, lead author of this review, has been involved in the care of children with CF for over 30 years, and has a deep appreciation of the impact of...
Source: Cochrane News and Events - December 16, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news
How Is a Person's Life Affected By Cystic Fibrosis?
Title: How Is a Person ' s Life Affected By Cystic Fibrosis?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 12/10/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 10, 2020 Category: Respiratory Medicine Source Type: news
Johns Hopkins develops potential antibiotic for drug-resistant pathogen
(Johns Hopkins University) Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis and other lung ailments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2020 Category: International Medicine & Public Health Source Type: news
FDA approves Xolair ® (omalizumab) for adults with nasal polyps
Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news
FDA approves Xolair ® (omalizumab) for adults with nasal polyps
Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news
Telehealth Finds Acceptance Among Patients With Cf, Clinicians Telehealth Finds Acceptance Among Patients With Cf, Clinicians
Telehealth is widely accepted among individuals with cystic fibrosis (CF) and the physicians who treat them, according to three new studies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
COVID-19 rapid guideline: cystic fibrosis, NICE (updated 7th October 2020)
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.The guideline focuses on what you need to stop or start doing during the pandemic. Follow the usual professional guidelines, standards and laws (including those on equalities, safeguarding, communication and mental capacity), as described in 2 External 0 0 0 making decisions using NICE guidelines false https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/making-decisions-using-nice-guidelines true false%>. On 7 October 2020,...
Source: Current Awareness Service for Health (CASH) - November 20, 2020 Category: Consumer Health News Source Type: news
Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?
Title: Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?Category: Procedures and TestsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/20/2020 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - November 20, 2020 Category: Pediatrics Source Type: news
Understanding lung infections in patients with cystic fibrosis
(University of Warwick) For young people with cystic fibrosis, lung infection with Staphylococcus aureus, MRSA, is common and is treated with antibiotics in the hope that this will prevent a decline in lung function. However there has recently been debate over the role S. aureus plays in CF lung disease. Researchers from the University of Warwick have used a new model of CF lungs which could be used to make better decisions about future use of antibiotics. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 19, 2020 Category: Infectious Diseases Source Type: news
Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 18, 2020 Category: American Health Authors: Ron Leuty Source Type: news
Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection
Clinicians treating patients with cystic fibrosis have had to face the possibility that their patients may be at greater risk of worse outcomes from COVID-19.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - November 11, 2020 Category: Emergency Medicine Tags: Pulmonary Medicine News Source Type: news
